Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $6.3 million.

  • Ani Pharmaceuticals' Cash from Financing Activities fell 97.82% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 103.96%. This contributed to the annual value of $264.9 million for FY2024, which is 292.87% up from last year.
  • Ani Pharmaceuticals' Cash from Financing Activities amounted to $6.3 million in Q3 2025, which was up 463.19% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cash from Financing Activities ranged from a high of $291.0 million in Q3 2024 and a low of -$19.7 million during Q1 2024.
  • In the last 3 years, Ani Pharmaceuticals' Cash from Financing Activities had a median value of -$1.7 million in 2025 and averaged $29.7 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash from Financing Activities soared by 8,226.99% in 2021 and then crashed by 2,246.06% in 2023.
  • Ani Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $179.4 million in 2021, then crashed by 100.28% to -$508,000 in 2022, then slumped by 2,246.06% to -$11.9 million in 2023, then soared by 58.83% to -$4.9 million in 2024, then plummeted by 97.82% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, -$1.7 million for Q2 2025, and -$9.9 million during Q1 2025.